Continued Agency Strides Towards IRA Negotiation Program Imp

On June 30, 2023, the Centers for Medicare & Medicaid Services ("CMS") issued its final guidance memorandum1 (the "Final Guidance") on the implementation of the Inflation Reduction Act ("IRA") Medicare Drug Price Negotiation Program for the Initial Price Applicability Year of 2026.

Related Keywords

, Negotiation Program Agreement , Medicare Drug Price Negotiation Program Agreement , Medicare Drug Price Negotiation Program , Centers For Medicare Medicaid , Office Of Inspector , Inflation Reduction Act , Initial Price , Applicability Year , Final Guidance , Maximum Fair Price , Initial Guidance , Initial Year , Selected Drug , Further Clarification , Regarding Drugs , Will Be Excluded , Selected Drugs , Fide Marketing , Requirements Imposed , New Drug Application , Biologics License , Including Divestiture , Social Security , Ensure Access , Select Drug , Medicare Advantage Plans , Civil Monetary Penalties , Inspector General , Interested Parties , Drug Price Negotiation Program , Revised Guidance , Social Security Act , Initial Price Applicability Year , Approved Blood Products , Manufacturer Agreement Instructions , Medicare Drug Price , Negotiation Program ,